CLINICAL_TRIALS
research
· 2017-01-18
Clinical Trial Update: Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Summary
A completed post-marketing commitment trial update for sunitinib in renal cell carcinoma with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Status: COMPLETED | Results posted: 2017-01-18